HGH & Peptides

Sort By:  
Tesamorelin is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces growth hormone (GH) in a specific and physiological manner. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.
30.00€
A synthetically derived peptide that is being used in a wide range of skin-care and makeup products, especially those claiming to have a muscle-relaxing effect similar to Botox injections. These claims typically have to do with relaxing muscle contractions when making facial expressions
20.00€
AOD9604 is also known as tyr-somatostatin 177-191; it belongs to class of synthetic peptides and consists of 14 amino acids. Its molecular formula is C78H13O23S2 and its molecular mass is 1815.1.
45.00€
BPC-157, BPC 15 peptide by Canada Peptides BPC 157 5MG BPC 157, also known as BPC-157, BPC 15, or Booly Protection Compound 15, is a 15 amnio acid chain that possesses a molecular mass of 1419.53552. It has a molecular formula of C62H98N16O22
40.00€
CJC-1295 DAC 5mg peptide by Canada Peptides CJC-1295 is a tetrasubstituted peptide of 29 amino acid length, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was invented by ConjuChem, a Canadian biotechnology company. Purity: 98% (HPLC). CJC-1295 is sold in 2mg vials
30.00€
CJC-1295 DAC is a long-acting version of GHRH (Growth Hormone Releasing Hormone) which has had its half-life extended to 8 days. This is convenient as it means the product only needs to be injected once or twice per week for continuously elevated levels of Human Growth Hormone (HGH) and IGF-1
45.00€
DES [1-3] IGF-1: DES IGF-1 is an IGF-1 variant, and like IGF-1 LR3 mentioned above, it displays all the same characteristics as its cousin, such as the ability to cause muscle cell differentiation, the inhibition of muscle cell apoptosis, increased nutrient shuttling capacity, as well as anabolic
10.00€
Follistatin, also known as Activin-binding protein and FST, is a secreted protein. Follistatin / FST is an autocrine glycoprotein that is expressed in nearly all tissues of higher animals. Follistatin / FST contains 3 follistatin-like domains, 3 Kazal-like domains and 1 TB (TGF-beta binding) domain. Follistatin / FST is produced by folliculostellate (FS) cells of the anterior pituitary.
80.00€
Follistatin, also known as Activin-binding protein and FST, is a secreted protein. Follistatin / FST is an autocrine glycoprotein that is expressed in nearly all tissues of higher animals.
70.00€
GHRP-6 (Growth Hormone Releasing Peptide – 6) is a hexapeptide with a chain comprised of 6 amino acids. This sequence is considered to provide a signal to the body to begin secreting Growth Hormone(GH) release while also blocking Somatostatin, a hormone that inhibits Growth Hormone release.
25.00€
Chorionic gonadotropin is a drug whose actions are almost the same as those of luteinizing hormone (LH), which is produced by the pituitary gland. It is a hormone also normally produced by the placenta in pregnancy. Chorionic gonadotropin has different uses for females and males.
15.00€
Gonadorelin (also referred to as Gonadorelin Acetate) is a synthetically produced gonadotropin-releasing hormone (GnRH)
15.00€
GHRP-2 is a 2nd generation GHRP just behind GHRP-6. Compared to GHRP-6, GHRP-2 is considered to be much more superior in terms of growth hormone stimulation because over longer periods of time it maintains maximum elevations in Growth Hormone.
25.00€
Insulin-like growth factor 1 (IGF-1) also known as somatomedin C or mechano growth factor is a protein that in humans is encoded by the IGF1gene.[1][2] IGF-1 has also been referred to as a "sulfation factor"[3] and its effects were termed "nonsuppressible insulin-like activity" (NSILA) in the 1970s.
70.00€
Starting with the compound NNC 26-0194 [3-(4-imidazolyl) propionyl-D-Phe-Ala-Trp-D-Phe (CH2NH) Lys-ol], Novo Nordisk researchers have developed NNC 26-0161 (ipamorelin)1. Ipamorelin is able to induce a massive release of GH, being active by the intravenous (i.v.), intra-muscular, subcutaneous and oral routes and, interestingly, also by the iontophoresis transdermal route2.
25.00€
DSIP is an amphiphilic peptide of molecular weight 850 daltons with the amino acid motif: N-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-C.
20.00€
Melanotan II is a cyclic heptapeptide analog of the alpha-melanocyte stimulating hormone (a-MSH), with the following molecular structure: It has been described to have superpotentmelanotropic activity in vitro. Its effect on tanning, like the effect of its similar peptide
25.00€
MGF
Mechano growth factor (MGF) is a novel splice variant of the Insulin-Like Growth Factor-1 (IGF-1), also known as IGF-1 Ec in humans and IGF-1Eb in rodents. It is actually originally called MGF because the RNA form of it is expressed in muscle tissues in response to the overload or/and damage of muscle growth tissue
15.00€
Palmitoyl Oligopeptide (Pal-GHK) is a peptide speculated to mention the degradation of the matrix of the skin. Once fibroblasts, the cells that generate the skin matrix pick out higher ranges of GHK
28.00€
Tesamorelin (Tesamorelin)
Tesamorelin is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces growth hormone (GH) in a specific and physiological manner. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.

A peptide that increases growth hormone release improved several measures of cognitive function in cognitively normal and mildly impaired older individuals in a placebo-controlled trial, a researcher said here. Scores on standard tests of executive function and verbal memory were significantly higher in participants given tesamorelin (Egrifta), a synthetic analog of growth hormone releasing hormone (GHRH), in a 20-week trial, according to Laura D. Baker, PhD.. Participants taking the drug in the 78-person trial also reported greater subjective improvement in cognition relative to the placebo group.

In animal studies, GHRH administration improved biomarkers of brain function as well as performance on cognition tests. And a 2006 clinical trial with GHRH found small but significant improvements in cognitive test scores in healthy older adults. In the current study, funded by the National Institute on Aging, 41 cognitively normal adults and 37 with mild cognitive impairment were randomized to placebo or tesamorelin at 1 mg/day subcutaneously.

Mean participant age was 66 to 70 among the four groups. Scores on the Mini-Mental State Examination averaged 29 for the normal participants and 28 for those with mild impairments. Normal and impaired participants differed more at baseline on a test of story recall, with mean scores of 54 and 44, respectively. Tesamorelin appeared to have a protective effect relative to placebo among the cognitively impaired patients on this measure. At the final evaluation, scores declined an average of five points with placebo, whereas those assigned to tesamorelin had a mean decline of less than one point 

Specification
POTENCY
Quantity2
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation2 milligrams per vial
Tesamorelin is a stabilized analogue of the growth hormone-releasing factor (GRF) that induces growth hormone (GH) in a specific and physiological manner. To date, clinical studies suggest that Tesamorelin reduces visceral fat in HIV-infected patients with abdominal lipo-hypertrophy as well as reducing abdominal fat in all individuals studied.
30.00€
Acetyl Hexapeptide-3 (Acetyl Hexapeptide-3)

A synthetically derived peptide that is being used in a wide range of skin-care and makeup products, especially those claiming to have a muscle-relaxing effect similar to Botox injections. These claims typically have to do with relaxing muscle contractions when making facial expressions, thus reducing the appearance of expression lines.

The company selling acetyl hexapeptide-3 (trade name Argireline), Centerchem (www.centerchem.com), is based in Spain. According to their Web site, "Argireline works through a unique mechanism which relaxes facial tension leading to a reduction in superficial facial lines and wrinkles with regular use. Argireline has been shown to moderate excessive catecholamines release." Whether or not that is true when applied topically is only is only from Centerchem’s information. There is no published research substantiating any use of Argireline topically on skin.

Catecholamines are compounds in the body that serve as neurotransmitters such as epinephrine, adrenaline, and dopamine. Epinephrine is a substance that prepares the body to handle emergencies such as cold, fatigue, and shock. A deficiency of dopamine in the brain is responsible for the symptoms of Parkinson's disease. None of that sounds like something you want a cosmetic to inhibit or reduce. If acetyl hexapeptide-3 really worked to relax facial muscles, it would work all over the face (assuming you’re using the products as directed). If all the muscles in your face were relaxed you’d have sagging, not youthful, skin, not to mention it would affect your hand (you apply it with your fingers) which would inhibit you from picking up a cup or holding the steering wheel of your car.

For all the fear espoused by companies featuring this peptide in their “works like Botox” products, there is considerably more efficacy, usage, and safety documentation available for Botox. Despite claims being made for acetyl hexapeptide-3 (argireline), there is a clinical study revealing that this ingredient is not even remotely as effective as Botox in reducing wrinkles (Source: www.cremedevie.com/clinical_details.htm; International Journal of Cosmetic Science, October 2002).>/p>

It is also interesting to note, that even Botox when applied topically on skin has no impact on the skin or muscles in any way shape or form! (Source:Cosmetic Dermatology, July 2005, pages 521-524.) Still, like all peptides, acetyl hexapeptide-3 has water-binding properties and theoretical cell-communicating ability. It's not a throwaway ingredient, but it's also not as miraculous as the manufacturer would lead you to believe.

Specification
POTENCY
Quantity1
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation1 milligrams per vial
A synthetically derived peptide that is being used in a wide range of skin-care and makeup products, especially those claiming to have a muscle-relaxing effect similar to Botox injections. These claims typically have to do with relaxing muscle contractions when making facial expressions
20.00€
AOD9604 cyclized sequence (AOD9604)

AOD9604 is also known as tyr-somatostatin 177-191; it belongs to class of synthetic peptides and consists of 14 amino acids. Its molecular formula is C78H13O23S2 and its molecular mass is 1815.1.

To date, in 1978 scientists Ng and Borstein suggested that functionality of few proteins including AOD9604 might be dependent on both informational sequence and proper physical configuration. Since this protein also represents hormones and is also defined as analogue (synthetic) of growth hormone, researchers (Monash University) more than a decade ago conducted study with animal model about its metabolic effects on obesity and found that fragment 176-191 targets obese fat cells not lean cells, and furthermore has no adverse effects on insulin sensibility.

This research compound is a bit modified form of 14 amino acids of GH polypeptide; recently scientists found that it's responsible for controlling fat-reducing effect of initial polypeptide. Tyr-somatostatin is able to stimulate lipolysis and to slow down lipogenesis and to improve cholesterol level. Due to being rich in proline and providing high accessibility for proteases this compound influences conformational alterations in cytoplasmic domain of triple erythrocytes’ membrane.

Currently this fragment of hGH should be used for research purposes only.

AOD is a peptide 15 amino acids long which mimics a small portion of the growth hormone that has the fat reducing effects (increases fat metabolism).  It works by mimicking the way natural growth hormone regulates fat metabolism but without the adverse effects on blood sugar and growth that is seen if unmodified growth hormone is given.  It stimulates lipolysis (break down of fat) and inhibits lipogenesis (non fat food being stored in the body as fat).

AOD has been shown to target abnormal fat stores, and to prevent fat from being stored in the cells.  Studies have shown that it reduces the most stubborn fat regions (like abdominal fat).   It also has other benefits including increasing muscle mass, increasing IGF-1 (insulin growth factor) in a positive way to metabolise fat, and increase the amount of energy burned for the same amount of activity.

Other benefits which have been shown include an improvement in osteoarthritis.  It does this by increasing cartilage and collagen production in the joints to increase the thickness and repair some of the damage.  It has been shown to improve muscle, tendon and ligament repair, improve bone density which may have positive effects on osteoporosis.

AOD is given daily either as an injection or transdermal cream.  The effects are accumulative and continue to improve while taking it.

Specification
DOSAGE
Quantity250
UnitMicrograms
Timehours
POTENCY
Quantity5
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation5 milligrams per vial
AOD9604 is also known as tyr-somatostatin 177-191; it belongs to class of synthetic peptides and consists of 14 amino acids. Its molecular formula is C78H13O23S2 and its molecular mass is 1815.1.
45.00€
BPC 157 (Peptide) (BPC 157)

BPC 157 5MG BPC 157, also known as BPC-157, BPC 15, or Booly Protection Compound 15, is a 15 amnio acid chain that possesses a molecular mass of 1419.53552. It has a molecular formula of C62H98N16O22.

The Functionality of BPC 157
According to scientific study that has been conducted on animal test subjects, BPC 157 has been shown to possess anti-ulcer peptidgeric properties. What this means is, it has shown an ability to provide a means of regulatory control over the digestive tract’s overall functionality. It has been determined that this function protects the endothelium and promotes the process of angiogenesis. These particular functions can be related to several other functions that have been connected to the peptide, including wound healing and blood flow regulation throughout an animal test subject’s gastro-intestinal tract. Additionally, BPC 157’s functionality has been shown to be linked to anti-inflammatory properties.

BPC 157 and the Gastro-Intestinal Tract
Because of the way in which BPC 157’s inherent mechanics operate in conjunction with an animal test subject’s digestive tract, scientific studies have produced several hypothetical ways in which the peptide could provide aid regarding specific functions pertaining to the gastro-intestinal tract. For instance, it is thought that the peptide’s wound-healing and anti-inflammatory properties could provide aid in the treatment to various inflammatory bowel diseases such as Chron’s disease and ulcerative colitis. The anti-inflammatory properties have also allowed the peptide to be linked to conceivable quelling the effects of periodontitis around the teeth.

Purely for Scientific Research
Despite the fact that there has been plenty of research on BPC 157 in relation to how it functions and the benefits that can be derived from such functionality, it should be emphasized that the peptide is still just intended for scientific study at this point in time. Because of this, any findings or observations relating to BPC 157’s overall functionality, mechanics, benefits, should exclusively be the product of study performed in a strictly contained environment.

Specification
POTENCY
Quantity5
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation5 milligrams per vial
BPC-157, BPC 15 peptide by Canada Peptides BPC 157 5MG BPC 157, also known as BPC-157, BPC 15, or Booly Protection Compound 15, is a 15 amnio acid chain that possesses a molecular mass of 1419.53552. It has a molecular formula of C62H98N16O22
40.00€
CJC-1295 (CJC-1295)

CJC-1295 is a tetrasubstituted peptide of 29 amino acid length, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was invented by ConjuChem, a Canadian biotechnology company. Purity: 98% (HPLC). CJC-1295 is sold in 2mg vials.

CJC-1295 DAC has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC - 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.

is a long acting Growth Hormone Releasing Hormone, which causes the anterior pituitary  to release more growth hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).


 

CJC-1295 DAC Peptide Structure and Sequence

cjc-1295 dac

 

 

 

 

 

 

 

 

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 (Drug Affinity Complex) 
Molecular formula: C165H269N47O46
Molar Mass: 3647.15
CAS number: 863288-34-0

CJC-1295 DAC

CJC-1295 DAC vs. CJC-1295 No DAC

CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse of Human Growth Hormone

ConjuChem and The Development of CJC-1295 DAC

CJC-1295 DAC is a tetrasubstituted peptide analogue of Growth Hormone Releasing Hormones with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. A Canadian biotechnology company called ConjuChem had invented CJC-1295. Clinical Research on CJC-1295 first began during the mid-2000s. The goal of the peptide, acting to raise hgh like Ipamorelin, was to treat visceral fat deposits in obese AIDS patients because it is presumed that increased levels of exogenous hgH increase fat loss, or lipolysis. In one study, results showed that the measured GH release in rats over a two hour period showed that CJC-1295 released twice as much GH as CJC-1293 DAC. This result makes it preferable for immediate effectiveness as a result of the longer peak. With the use of a Growth Hormone Releasing Peptide (GHRP), such as Growth Hormone Releasing Hexapeptide (GHRP-6) in conjuction with CJC-1295 DAC, a study has shown that the GHRP’s create a Growth Hormone pulse which helps the CJC-1295 work effectively. Clinical research's involving CJC-1295 have shown that it had been successful for most research subjects.

Specification
POTENCY
Quantity2
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation2 milligrams per vial
CJC-1295 DAC 5mg peptide by Canada Peptides CJC-1295 is a tetrasubstituted peptide of 29 amino acid length, primarily functioning as a growth hormone releasing hormone (GHRH) analog. It was invented by ConjuChem, a Canadian biotechnology company. Purity: 98% (HPLC). CJC-1295 is sold in 2mg vials
30.00€
CJC-1295 with DAC (CJC-1295 with DAC)

CJC-1295 DAC has shown some amazing results as a growth hormone releasing hormone (GHRH) analog. Not only has CJC-1295 shown the ability to increase growth hormone and IGF-I secretion and its benefits, but it has been able to do so in very large amounts. Recent research studies have shown that CJC - 1295 stimulates GH and IGF-1 Secretion, and will keep a steady increase of HGH and IGF-1 with no increase in prolactin, leading to intense fat loss, and increases protein synthesis.

is a long acting Growth Hormone Releasing Hormone, which causes the anterior pituitary  to release more growth hormone. GHRH is released in pulses in the body, which alternate with corresponding pulses of somatostatin (growth-hormone inhibiting-hormone). Clinical Research was first conducted for CJC-1295 during the mid-2000s. The objective of the peptide was to treat visceral fat deposits in obese AIDS patients, as increased levels of exogenous hgH are presumed to increase lipolysis (fat loss). The clinical research was ultimately successful for most research subjects. Ghrelin, released from the gut, which circulates and acts as a hunger hormone, has synergistic activity in the body with GHRH and also suppresses somatostatin to make way for the GHRH pulse. Studies shows that combining a GHRP-6 with CJC 1295 DAC, significantly increase the release of GH and IGF-1 production without an increase in prolactin. An example of a GHRP (GH Releasing Peptide) is Hexarelin or GHRP-2. CJC 1295 DAC is a exceptionally designed peptide and is known for being the finest of the hGH secretogues. The DAC (Drug Affinity Complex) portion increases the half-life by binding with serum albumin and protects the CJC-1295 DAC peptide from degradation. This was formed when a lysine link was bounded to DACs to a reactive chemical called maleimidoproprionic acid (MPA).

CJC-1295 DAC vs. CJC-1295 No DAC

CJC-1295 DAC and CJC-1295 (also known as Modified GRF 1-29) are both Growth Hormone Releasing Hormones (GHRH). Their action in the human body is identical but the difference between the two peptides are the span of the half-life. Modified GRF 1-29 and Sermorelin have a very short acting half-life of about 30 minutes, while CJC-1295 DAC has a half-life that can last up to approximately 8 days. Many a scientist have reported that the short half-life of Sermorelin and Modified GRF 1-29 is considered to be much more natural as they produce a short pulse of Human Growth Hormone.

 

ConjuChem and The Development of CJC-1295 DAC

CJC-1295 DAC is a tetrasubstituted peptide analogue of Growth Hormone Releasing Hormones with D-Ala, Gln, Ala, and Leu substitutions at positions 2, 8, 15, and 27 respectively. A Canadian biotechnology company called ConjuChem had invented CJC-1295. Clinical Research on CJC-1295 first began during the mid-2000s. The goal of the peptide, acting to raise hgh likeIpamorelin, was to treat visceral fat deposits in obese AIDS patients because it is presumed that increased levels of exogenous hgH increase fat loss, or lipolysis. In one study, results showed that the measured GH release in rats over a two hour period showed that CJC-1295 released twice as much GH as CJC-1293 DAC. This result makes it preferable for immediate effectiveness as a result of the longer peak. With the use of a Growth Hormone Releasing Peptide (GHRP), such as Growth Hormone Releasing Hexapeptide (GHRP-6) in conjuction with CJC-1295 DAC, a study has shown that the GHRP’s create a Growth Hormone pulse which helps the CJC-1295 work effectively. Clinical research's involving CJC-1295 have shown that it had been successful for most research subjects

Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-LysLys(Maleimidopropionyl)-NH2 (Drug Affinity Complex) 
Molecular formula: C165H269N47O46
Molar Mass: 3647.15

DOSAGE
Quantity1 or 2
UnitMilligram/Milliliter
Timeweek
POTENCY
Quantity2
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation2 milligrams per vial
CJC-1295 DAC is a long-acting version of GHRH (Growth Hormone Releasing Hormone) which has had its half-life extended to 8 days. This is convenient as it means the product only needs to be injected once or twice per week for continuously elevated levels of Human Growth Hormone (HGH) and IGF-1
45.00€
DES(1-3) IGF (DES(1-3) IGF)
DES [1-3] IGF-1:
DES IGF-1 is an IGF-1 variant, and like IGF-1 LR3 mentioned above, it displays all the same characteristics as its cousin, such as the ability to cause muscle cell differentiation, the inhibition of muscle cell apoptosis, increased nutrient shuttling capacity, as well as anabolic & anti-catabolic effects. Structurally, DES differentiates itself from standard IGF-1, in that has been molecularly modified by cleaving 3 molecules from the IGF-1 chain. This results in a truncated form of IGF-1, which is almost 5X more potent than IGF-1 LR3 and a full 10X more potent than standard IGF-1.
That is not all. DES also has a very low affinity for binding proteins at only 1%, making DES an extremely usable form of IGF-1, while as much as 98% of standard IGF-1 will become bound to binding proteins and remain inactive, unavailable for use by skeletal muscle tissue. DES also has the ability to attach to lactic acid deformed receptor sites (during training, lactic acid build-up in muscle tissue can temporarily deform IGF-1 receptor sites, preventing IGF-1 from attaching to them during this period), allowing it to turn-on our muscle-building machinery during training.

The down-side to DES is that it possesses a relatively short half-life of about 20 minutes in length, compared to IGF-1 LR3, which will stay active for about a day. Because of the differences between the LR3 and DES versions of IGF-1, they are often used in different ways and for different purposes. One use for which DES has proven effective is in the area of site enhancement. Due to DES’s short active-life, the hormone will only circulate systematically for a relatively short period of time before becoming inactive. This means that the majority of DES’s active life will be spent at the injection site, affecting the target muscle to a greater degree in comparison to the rest of the body. Through DES’s impressive ability to stimulate muscle cell hyperplasia and combined with its potent anabolic activity, many users have reported significant and long-term changes in the size & shape of the treated muscle with regular use. 

* Shuttles nutrients directly into cells and muscles for maximum results.
* Builds muscle mass, promotes fat loss.
* Increased protein synthesis.
* IGF mobilizes fat for use as energy in adipose tissue.
* Causes hyperplasia, the increase of more muscle cells.
* At a genetic level it has the potential to alter an individuals capacity to build superior muscle density and size.
* Possesses the ability to rehabilitate damaged cartilage.

DOSAGE
Quantity20-50
UnitMicrograms
Timeday 
POTENCY
Quantity0,2
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation20 micrograms per vial
DES [1-3] IGF-1: DES IGF-1 is an IGF-1 variant, and like IGF-1 LR3 mentioned above, it displays all the same characteristics as its cousin, such as the ability to cause muscle cell differentiation, the inhibition of muscle cell apoptosis, increased nutrient shuttling capacity, as well as anabolic
10.00€
Follistatin 344 (Follistatin 344)
Follistatin, also known as Activin-binding protein and FST, is a secreted protein. Follistatin / FST is an autocrine glycoprotein that is expressed in nearly all tissues of higher animals. Follistatin / FST contains 3 follistatin-like domains, 3 Kazal-like domains and 1 TB (TGF-beta binding) domain. Follistatin / FST is produced by folliculostellate (FS) cells of the anterior pituitary. FS cells make numerous contacts with the classical endocrine cells of the anterior pituitary including gonadotrophs. Isoform 1 of Follistatin / FST is the predominant isoform in serum but is undetectable in follicular fluid. Follistatin / FST is a specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH). Follistatin / FST binds directly to activin and functions as an activin antagonist. Follistatin / FST was initially isolated from follicular fluid and was identified as a protein fraction that inhibited follicle-stimulating hormone (FSH) secretion from the anterior pituitary, and so was known as FSH-suppressing protein (FSP). Follistatin / FST and BMPs are known to play a role in folliculogenesis within the ovary. The main role of Follistatin / FST in the oestrus/menstrus ovary appears to be progression of the follicle from early antral to antral/dominant, and importantly the promotion of cellular differentiation of the estrogen producing granulosa cells (GC) of the dominant follicle into the progesterone producing large lutein cells (LLC) of the corpus luteum.


POTENCY
Quantity1
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation1 milligrams per vial
Follistatin, also known as Activin-binding protein and FST, is a secreted protein. Follistatin / FST is an autocrine glycoprotein that is expressed in nearly all tissues of higher animals. Follistatin / FST contains 3 follistatin-like domains, 3 Kazal-like domains and 1 TB (TGF-beta binding) domain. Follistatin / FST is produced by folliculostellate (FS) cells of the anterior pituitary.
80.00€
Follistatin (follistatin)
Follistatin, also known as Activin-binding protein and FST, is a secreted protein. Follistatin / FST is an autocrine glycoprotein that is expressed in nearly all tissues of higher animals. Follistatin / FST contains 3 follistatin-like domains, 3 Kazal-like domains and 1 TB (TGF-beta binding) domain. Follistatin / FST is produced by folliculostellate (FS) cells of the anterior pituitary. FS cells make numerous contacts with the classical endocrine cells of the anterior pituitary including gonadotrophs. Isoform 1 of Follistatin / FST is the predominant isoform in serum but is undetectable in follicular fluid. Follistatin / FST is a specific inhibitor of the biosynthesis and secretion of pituitary follicle stimulating hormone (FSH). Follistatin / FST binds directly to activin and functions as an activin antagonist. Follistatin / FST was initially isolated from follicular fluid and was identified as a protein fraction that inhibited follicle-stimulating hormone (FSH) secretion from the anterior pituitary, and so was known as FSH-suppressing protein (FSP). Follistatin / FST and BMPs are known to play a role in folliculogenesis within the ovary. The main role of Follistatin / FST in the oestrus/menstrus ovary appears to be progression of the follicle from early antral to antral/dominant, and importantly the promotion of cellular differentiation of the estrogen producing granulosa cells (GC) of the dominant follicle into the progesterone producing large lutein cells (LLC) of the corpus luteum.

POTENCY
Quantity1
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation1 milligrams per vial
Follistatin, also known as Activin-binding protein and FST, is a secreted protein. Follistatin / FST is an autocrine glycoprotein that is expressed in nearly all tissues of higher animals.
70.00€
GHRP-6 (GHRP-6)

The Development of GHRP-6

In 1982, the natural hormone "Growth Hormone Releasing Hormone" (GHRH) was identified after a prolonged search. Soon, researchers discovered that those GH-Releasing Peptides (specifically GHRP-6 & GHRP-2) followed a mode of action which bound them to and was mediated through receptors different from those for GHRH. Furthermore, researches discovered that these GH-Releasing Peptides acted synergistically with the natural hormone Growth Hormone Releasing Hormone (GHRH), which is related to Sermorelin, in both laboratory animals and humans to produce large releases of Growth Hormone. In the 1980s, the first highly potent GH-Releasing peptide, GHRP-6, was developed. Due to a strong GH release response from the the peptide, it became the first member of a class called Growth Hormone secretagogues. GHRP-6 is a hexapeptide composed of 6 amino acids: L-Histidine, D-Tryptophan, L-Alanine, L-Tryptophan, D-Phenylalanine and L-Lysine. The "L" form of an amino acid is the naturally occurring form and often in the nomenclature the "L" is dropped. The "D" form does not occur in nature and is the isomeric form (i.e. mirror image) of the naturally occurring "L" form. GHRP-6 (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is composed of both natural and isomeric forms of those 6 amino acids.This sequence provides a signal to the body to begin secreting Growth Hormone release while also blocking Somatostatin, a hormone that inhibits the release of Growth Hormone.

Studies Related to the GHRP-6 Peptide

Investigations reported that GHRP-6 is more efficient than GHRH itself in monkeys and performs synergistically when combined or applied together. An example of this combination would be GHRP-2 and CJC-1295. GHRP-6 is believed to be acting naturally on both pituitary and hypothalamic sites (Fairhall et al. 1995). In a time-dependent and dose-dependent manner, the primary pituitary cells of rats were demonstrated on. From the studies, the concentrations of the GHRP-6 needed for the half-maximal and maximal stimulation were 7 x 10(-9) and 10(-7) M, respectively.

In another study, it was concluded that the major target of the GHRP-6 in vivo (both laboratory animals and humans) is the hypothalamus. From the observation, it was concluded that the GH release induced by the central GHRP-6 injections in guinea pigs was inhibited by the central action of somatostatin. Furthermore, an inhibition by somatostatin with the activated GRF neurons, induced by GHRP-6, was observed via receptors known to be located on or near the GRF themselves. This particular experiment further indicated that GHRP-6 is effectively stimulating GH release from somatotrophs through different receptors, the mechanisms of which are not yet known (Chan et al. 1989).

Determining how efficient and the actions of the growth hormone is dependent on the physical condition of the experimental unit. For example, in humans, GH secretion decreases with obesity. On the other hand, GHRP-6, similar to Hexarelin, showed in one case increased (almost twice that of GHRP) GH responses when administered in obese patients (Cordido et al. 1993). Though obesity has shown affecting the efficiency of the hormone, it was also suggested that GHRP-6’s effects were found to be sex- and age-independent without being affected by the noadregenic pathways using the a2 adrenergic receptors (Penalva et al. 2008).

GHRP-6 and the Growth Hormone Secretagogue Receptor

GHRPs are not simply surrogates of GHRH, instead GHRP-6 is an artificial activator of a separate newly discovered receptor called Growth Hormone Secretagogue Receptor (GHS-R). Soon Ghrelin was discovered, the endogenous ligand that binds to the GHS-R. Both Ghrelin and all the synthetic compounds such as GHRP-6 were termed "Growth Hormone Secretagogues" (GHSs). One side effect of GHRP-6 is a significant increase in appetite due to stimulating the release of Ghrelin, a peptide that is released naturally in the lining of the stomach that increases hunger and gastric emptying. Also, GHRP-6 causes stimulation of the anterior pituitary gland which causes an increase in Growth Hormone release. The increased amounts of Growth Hormone can cause the liver to secrete the hormone IGF-1, which improves the animal body’s ability to burn fat and build muscle. Since GHRP-6 acts directly on the feedback loop which signals the inhibition of Growth Hormone release, GHRP-6 can re-stimulate the production of Growth Hormone.

COMMON
Active substanceGrowth Hormone Releasing Peptide
POTENCY
Quantity5
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation5 milligrams per vial
GHRP-6 (Growth Hormone Releasing Peptide – 6) is a hexapeptide with a chain comprised of 6 amino acids. This sequence is considered to provide a signal to the body to begin secreting Growth Hormone(GH) release while also blocking Somatostatin, a hormone that inhibits Growth Hormone release.
25.00€
Gonadotropin (HCG) (Gonadotropin)
Chorionic gonadotropin is a drug whose actions are almost the same as those of luteinizing hormone (LH), which is produced by the pituitary gland. It is a hormone also normally produced by the placenta in pregnancy. Chorionic gonadotropin has different uses for females and males.

In females, chorionic gonadotropin is used to help conception occur. It is usually given in combination with other drugs such as menotropins and urofollitropin. Many women being treated with these drugs usually have already tried clomiphene alone (e.g., Serophene) and have not been able to conceive yet. Chorionic gonadotropin is also used in in vitro fertilization (IVF) programs.

In males, LH and chorionic gonadotropin stimulate the testes to produce male hormones such as testosterone. Testosterone causes the enlargement of the penis and testes and the growth of pubic and underarm hair. It also increases the production of sperm.

Although chorionic gonadotropin has been prescribed to help some patients lose weight, it should never be used this way. When used improperly, chorionic gonadotropin can cause serious problems.

Chorionic gonadotropin is to be administered only by or under the immediate supervision of your doctor.


DOSAGE
Quantity1000-4000
UnitIU
Timeweek
POTENCY
Quantity5000
UnitIU
PACKAGING
Quantity1
UnitVial
Presentation5000 IU per vial
Chorionic gonadotropin is a drug whose actions are almost the same as those of luteinizing hormone (LH), which is produced by the pituitary gland. It is a hormone also normally produced by the placenta in pregnancy. Chorionic gonadotropin has different uses for females and males.
15.00€
Hexarelin (Hexarelin)

Hexarelin (Hexarelin Acetate) is a synthetic hexapeptide in the growth factor family which stimulates the release of growth hormone (GH) and does not interfere with the body's ability to produce its own GH. Structurally, Hexarelin (Hexarelin Acetate) is similar in structure to GHRP-6 but without the appetite increase because of its inability to drastically increase Ghrelin levels which is responsible for the increased appetite and quicker gastric emptying. Hexarelin is a synthetic growth hormone secretagogue made from six amino acids. It contains powerful growth hormone releasing properties in the human body. Hexarelin in studies over a certain period has shown that it reduces visceral fat. Hexarelin (Hexarelin Acetate) like other Growth Hormone Releasing Peptides is most effective synergistically when administered with GHRH such as Sermorelin or Modified GRF 1-29. The increase of circulating GH through Hexarelin use causes levels of Insulin-Like Growth Factor (IGF-1) to rise in the liver. IGF-1 is the prime cause of muscle growth in response to GH stimulation. Users of IGF-1 typically experience increased strength and muscle mass, as well as a very pronounced fat loss.

The functionality of Hexarelin

Hexarelin (Hexarelin Acetate) is chemically designed as L-Histidyl-2-methyl-D-tryptophyl-L-alanyl-L-tryptophyl-D-phenylalanyl-L-lysinamide. Hexarelin (Hexarelin Acetate) is a potent GHRP-6 analog, whose structure (His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH2) creates a greater stability than GHRP-6 due to a substituted (2 Me)Trp. Hexarelin has a half-life of about 70 min, longer than that of GHRP-6. Replacement of the naturally occurring L-amino acids for the D-configuration results in these longer half-lives.

Growth Hormone Secretion

Hexarelin has shown that it is highly stimulated at 30 minutes after being induced by rapid and sustained GH secretion. The pituitary gland produces GH in the brain, in children this hormone helps them to grow and in adults it helps to maintain muscle and burn fat. In one sixteen-week study, it has been shown that GH levels return to normal after stopping use after four weeks

POTENCY
Quantity2
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation2 milligrams per vial
20.00€
GONADORELIN (GONADORELIN)

Gonadorelin (also referred to as Gonadorelin Acetate) is a synthetically produced gonadotropin-releasing hormone (GnRH). Gonadorelin primarily stimulates the synthesis and release of luteinizing hormone (LH) from the anterior pituitary gland. Follicle-stimulating hormone (FSH) production and release is also increased by gonadorelin, but to a lesser degree. In prepubertal females and some gonadal function disorders, the FSH response may be greater than the LH response.

Gonadorelin Acetate

Gonadotropin-releasing hormone, also known as follicle-stimulating hormone–releasing hormone (FSH-RH) or luteinizing hormone–releasing hormone (LHRH), is peptide hormone responsible for stimulating the anterior pituitary to release follicle-stimulating hormone (FSH) and luteinizing hormone (LH). GnrH is considered the initial step of the hypothalamic–pituitary–gonadal axis. At the pituitary, GnRH stimulates the synthesis and secretion of the gonadotropins, follicle-stimulating hormone (FSH), and luteinizing hormone (LH). These processes are controlled by the size and frequency of GnRH pulses, as well as by feedback from androgens and estrogens. Low-frequency GnRH pulses are required for FSH release, whereas high-frequency GnRH pulses stimulate LH pulses in a one to one manner.

GnRH is secreted in the hypophysial portal bloodstream at the median eminence.[1] The portal blood carries the GnRH to the pituitary gland, which contains the gonadotrope cells, where GnRH activates its own receptor, gonadotropin-releasing hormone receptor (GnRHR), a seven-transmembrane G-protein-coupled receptor that stimulates the beta isoform of Phosphoinositide phospholipase C, which goes on to mobilize calcium and protein kinase C. This results in the activation of proteins involved in the synthesis and secretion of the gonadotropins LH and FSH. GnRH is degraded by proteolysis within a few minutes.

POTENCY
Quantity2
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation2 milligrams per vial
Gonadorelin (also referred to as Gonadorelin Acetate) is a synthetically produced gonadotropin-releasing hormone (GnRH)
15.00€
GHRP-2 (GHRP-2)

GHRP-2 and GRF Analogue Interactions (CJC-1295 / Sermorelin)

It is important to know that GHRP-2 does not relate to any Growth Hormone Releasing Hormones (GHRH) peptides such asSermorelin and CJC-1295 because it acts on different receptors. However, greater results occurred when administered in conjunction with a Growth Hormone Releasing Hormone (GHRH) such as Modified GRF 1-29 or CJC-1295 DAC. Naturally, these GHRP-2 peptide receptors interact with a hormone called ghrelin. Growth hormone releasing peptide 2 is a commercially synthesized, non-natural super-analog of GHRP-6 which is capable of potent stimulatory effect on growth hormone (GH) secretion with slight stimulator effect in PRL, ACTH and levels of cortisol (Arvat et al. 1997). It is also a synthetic agonist of ghrelin that is binding with the growth hormone (GH) secretagogue receptor. GHRP-2 has been shown to affect and induce growth hormone secretion. The response of natural physiologic system includes increase in levels of calcium ion influx alongside with increased release of growth hormones in response to this peptide (Wu et al. 1994).

 

Comparing GHRP-2 and GHRP-6 (Growth Hormone Releasing Hexapeptide)

GHRP-2 is a 2nd generation GHRP just behind GHRP-6. Compared to GHRP-6, GHRP-2 is considered to be much more superior in terms of growth hormone stimulation because over longer periods of time it maintains maximum elevations in Growth Hormone. GHRP-2 has shown to increase IGF-1 levels (Insulinlike Growth Factor 1), and even greater results happen when used with Growth Hormone Releasing Hormone (GHRH). It has a short half life with peak concentrations occurring around 15 minutes but not longer than 60 minutes. The response of natural physiologic system includes increase in levels of calcium ion influx alongside with increased release of growth hormones in response to the high-amplitude pulsation from the GHRP-2. GHRP-2 and other ghrelin analogues increase the number of somatotropes involved in the GH pulse by inhibiting somatostatin, GHRH increases the pulse amplitude per pituitary cell or somatotrope by other means. Unlike ghrelin, GHRP-2 is not lipogenic which means that it does not induce fat storage. Although ghrelin plays a large role in hunger, GHRP-2 as an analog of ghrelin does not increase appetite significantly.

 

The Utility of GHRP-2 as a Growth Hormone Secretagogue

GHRP-2 has been studied extensively for its utility as a growth hormone secretagogue (GHS). Scientists have discovered that the Growth Hormone Releasing Peptide-2 increases the natural production of growth hormone (GH). In the early 90’s, one of the most famous studies was performed and later published in 1997 in the Journal of Endocrinology and Metabolism. This study further exemplifies the theory that growth hormone releasing peptides (including Ipamorelin and GHRP-6) could help hormone deficient adults and children. Ever since these major scientific studies, GHRP-2 has been widely produced. With other scientific labs confirming the results from their studies, GHRP-2 can in fact work for those who lack the ability to make adequate human growth hormone. Results however will differ with the use of GHRP-2 because species respond differently based on the pituitary somatotrophs and the differences in the subtypes of GHRP receptors. In the physiologic system, the actions are blocked by GRF receptors antagonist which acts through a different receptor to that employed by earlier GHRPs.

COMMON
Active substanceGrowth Hormone Releasing Peptide
POTENCY
Quantity5
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation5 milligrams per vial



GHRP-2 is a 2nd generation GHRP just behind GHRP-6. Compared to GHRP-6, GHRP-2 is considered to be much more superior in terms of growth hormone stimulation because over longer periods of time it maintains maximum elevations in Growth Hormone.
25.00€
IGF1 LR3 (IGF1-LR3)
Insulin-like growth factor 1 (IGF-1) also known as somatomedin C or mechano growth factor is a protein that in humans is encoded by the IGF1gene.[1][2] IGF-1 has also been referred to as a "sulfation factor"[3] and its effects were termed "nonsuppressible insulin-like activity" (NSILA) in the 1970s.

   IGF-1 is a hormone similar in molecular structure to insulin. It plays an important role in childhood growth and continues to have anabolic effects in adults. A synthetic analog of IGF-1, mecasermin is used for the treatment of growth failure.[4]

    IGF-1 consists of 70 amino acids in a single chain with three intramolecular disulfide bridges. IGF-1 has a molecular weight of 7649 daltons

    Synthesis and circulation

    IGF-1 is produced primarily by the liver as an endocrine hormone as well as in target tissues in a paracrine/autocrine fashion. Production is stimulated by growth hormone (GH) and can be retarded by undernutrition, growth hormone insensitivity, lack of growth hormone receptors, or failures of the downstream signalling pathway post GH receptor including SHP2 and STAT5B. Approximately 98% of IGF-1 is always bound to one of 6 binding proteins (IGF-BP). IGFBP-3, the most abundant protein, accounts for 80% of all IGF binding. IGF-1 binds to IGFBP-3 in a 1:1 molar ratio.

    In rat experiments the amount of IGF-1 mRNA in the liver was positively associated with dietary casein and negatively associated with a protein free diet.

    Mechanism of action

    Its primary action is mediated by binding to its specific receptor, the Insulin-like growth factor 1 receptor, abbreviated as ""IGF1R"", present on many cell types in many tissues. Binding to the IGF1R, a receptor tyrosine kinase, initiates intracellular signaling; IGF-1 is one of the most potent natural activators of the AKTsignaling pathway, a stimulator of cell growth and proliferation, and a potent inhibitor of programmed cell death.

    IGF-1 is a primary mediator of the effects of growth hormone (GH). Growth hormone is made in the anterior pituitary gland, is released into the blood stream, and then stimulates the liver to produce IGF-1. IGF-1 then stimulates systemic body growth, and has growth-promoting effects on almost every cell in the body, especially skeletal muscle, cartilage, bone, liver, kidney, nerves, skin, hematopoietic cell, and lungs. In addition to the insulin-like effects, IGF-1 can also regulate cell growth and development, especially in nerve cells, as well as cellular DNA synthesis.

    Deficiency of either growth hormone or IGF-1 therefore results in diminished stature. GH-deficient children are given recombinant GH to increase their size. IGF-1 deficient humans, who are categorized as having Laron syndrome, or Laron's dwarfism, are treated with recombinant IGF-1. In beef cattle, circulating IGF-I concentrations are related to reproductive performance.

COMMON
Active substanceInsuline-like Growth Factor
DOSAGE
Quantity1/2 or 1
UnitMilligram/Milliliter
Timeday 
POTENCY
Quantity1
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation1 milligrams per vial
Insulin-like growth factor 1 (IGF-1) also known as somatomedin C or mechano growth factor is a protein that in humans is encoded by the IGF1gene.[1][2] IGF-1 has also been referred to as a "sulfation factor"[3] and its effects were termed "nonsuppressible insulin-like activity" (NSILA) in the 1970s.
70.00€
Ipamorelin (Ipamorelin)

Ipamorelin is a penta-peptide hormone (Aib-His-D-2-Nal-D-Phe-Lys-NH2), a growth hormone secretagogue and a small molecule ghrelin mimetic developed by Novo Nordisk. Ipamorelin belongs to the most recent generation of GHRPs and causes significant release of growth hormone. Similar to GHRP-6 and GHRP-2, it suppresses somatostatin and increases the stimulation and release of Growth Hormone (GH) from the anterior pituitary. Currently, there are few clinical trials involving Ipamorelin, which were first being studied in the 90s. Somatotropes are the cells that are responsible for producing and releaseing GH.

The Ipamorelin Growth Hormone Releasing Peptide Comparison

Ipamorelin is a 3rd generation GHRP behind GHRP-6 and GHRP-2. Ipamorelin has very similar characteristics of GHRP-2: does not have ghrelin's lipogenic properties and does not promote hunger. Ipamorelin acts synergistically when applied during a Growth Hormone Releasing Hormone (GHRH) pulse or when it is administered along with a GHRH or an analog such asSermorelin or Modified GRF 1-29 (growth releasing factor, aminos 1-29). The synergy comes both due to the suppression of somatostatin and the fact that ipamorelin increases GH release per-somatotrope, while GHRH increases the number of somatotropes releasing GH. On the other hand, Ipamorelin is similar to GHRP-6 because they both release GH at a very similar strength minus the side effects that of GHRP-6. Both GHRP-6 and GHRP-2 cause a release and an increase in cortisol and prolactin levels, however Ipamorelin only selectively releases GH at any dose. Ipamorelin shares similar functionality toHexarelin and compared to other peptides, it is a much more stable form of ghrelin and has longer half-life periods of at least two hours long and causes secondary effect by making neurons to become excited.

 

Studies Related to Ipamorelin

Ipamorelin has been shown to be both highly potent and very selective in vivo and vitro situations, and has also demonstrated good safety and tolerability in human clinical studies. Research has shown that Ipamorelin is growth hormone specific which means that the pituitary hormones such as cortisol are unaffected. In one study, it was found that young female adult rats had increased bone mass due to 12 weeks of treatment with ipamorelin. This peptide compared to other Growth Hormone Releasing Peptides ensures the benefits without having to deal with possible negative side effects.

COMMON
Active substanceGrowth Hormone Secretagogue Receptor
POTENCY
Quantity5
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation5 milligrams per vial
Starting with the compound NNC 26-0194 [3-(4-imidazolyl) propionyl-D-Phe-Ala-Trp-D-Phe (CH2NH) Lys-ol], Novo Nordisk researchers have developed NNC 26-0161 (ipamorelin)1. Ipamorelin is able to induce a massive release of GH, being active by the intravenous (i.v.), intra-muscular, subcutaneous and oral routes and, interestingly, also by the iontophoresis transdermal route2.
25.00€
DSIP (DSIP)

DSIP is an amphiphilic peptide of molecular weight 850 daltons with the amino acid motif: N-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-C.

Delta sleep-inducing peptide, abbreviated DSIP, was first discovered in 1974 by the Swiss Schoenenberger-Monnier group who isolated it from the cerebral venous blood of rabbits in an induced state of sleep. It was primarily believed to be involved in sleep regulation due to its apparent ability to induce slow-wave sleep in rabbits, but studies on the subject have been contradictory.

It has been found in both free and bound forms in the hypothalamus, limbic system and pituitary as well as various peripheral organs, tissues and body fluids.[3] In the pituitary it co-localises with many peptide and non-peptide mediators such as corticotropin-like intermediate peptide (CLIP), adrenocorticotrophic hormone (ACTH), melanocyte-stimulating hormone (MSH), thyroid-stimulating hormone (TSH) and melanin concentrating hormone (MCH). It is abundant in the gut secretory cells and in the pancreas where it co-localises with glucagon.

POTENCY
Quantity2
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation2 milligrams per vial
DSIP is an amphiphilic peptide of molecular weight 850 daltons with the amino acid motif: N-Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu-C.
20.00€
Melanotan II (Melanotan II)

Melanotan 2 (also referred to as Melanotan II) is a synthetically produced variant of a peptide hormone naturally produced in the body that stimulates melanogenesis, a process responsible for pigmentation of the skin. This peptide hormone, called alpha-Melanocyte stimulating hormone or MSH, activates certain melanocortin receptors in the process of exerting its effects. Indeed, MSH also exerts potent influence over lipid metabolism, appetite, and sexual libido via these melanocortin receptors. As a result, Melanotan 2 has been shown in studies to exhibit appetite suppressant, lipolytic, and libido-enhancing effects in addition to promoting skin tanning. Melanotan 2 has been researched extensively for use in protecting against the harmful effects of ultraviolet radiation from sunlight due to its melanogenesis-stimulating properties. 

The Development of Melanotan 2

The initial creation of the synthetic Melanotan 2 peptide can be credited to the University of Arizona. During the course of research aimed at developing a defense against skin cancer, focus was placed on developing a method of stimulating natural melanogenesis, or the natural production of melanin in the skin, without direct exposure to the potentially harmful ultraviolet radiation in sunlight. Initially, University of Arizona researchers attempted to directly administer the naturally occurring hormone alpha-MSH in order to elicit this desired result. Although this strategy exhibited promising results, it was determined that the naturally occurring MSH had a prohibitively short half-life to be of realistic use as a therapeutic remedy. However, the positive results gleaned from MSH administration encouraged further research into the development of Melanotan 1 and Melanotan 2, which exhibit similar effects whilst possessing an extended half-life for functional therapeutic utilization.

 

Melanotan 2 Studies and Further Information

Melanotan and Melanotan 2 are both analogs of the peptide hormone alpha-melanocyte stimulating hormone (α-MSH) that tend to induce skin tanning. Unlike Melanotan 1, Melanotan 2 has been shown to have aphrodisiac properties, the additional effect of increasing libido. Melanotan 2 is a cyclic heptapeptide analog of the alpha-melanocyte stimulating hormone (a-MSH).

The effects of Melanotan 2 on the diet and food intake of the laboratory mice have also been investigated. It has been demonstrated that the central melanocortin (MC) has been activated by melanotan 2 when fed and induced in the mice. The six-day treatment of Melanotan 2 has shown that the peptide actually reduced the body weight and the adipose tissue in the viscera of the mice and suppressed the caloric intake of the organism. This has implications in clinical applications of the possible treatment to reduce carbohydrate or calorie intake especially for the overweight and the obese. Furthermore, the same study has also demonstrated that there was a sustained increase in the available oxygen consumption in obese animals. Melanotan 2 also helped reduced the level of serum insulin and the cholesterol levels when compared with the control treatments. Furthermore, it has been suggested that melanotan 2 actually lowers the level of acetylcholine A caboxylase expression and even prevented the reduction of carnitine and palmitoltransferase I mRNA in muscle-type tissues by pair-feeding in the muscles of the obese rats. Moreover, the Melanotan 2 peptide actually increased the fat catabolism in the muscles and even improved the cholesterol metabolism (Li et al. 2004). 

α-Melanocyte-Stimulating Hormone Analogues (Melanotan Peptides)

α-Melanocyte-stimulating hormone (α-MSH) is a naturally occurring endogenous melanotan peptide hormone of the melanocortin family, which is considered to be the most important of the melanocyte-stimulating hormones when it comes to stimulating melanogenesis, a process which in mammals is responsible for hair and skin pigmentation. α-MSH also plays a role in feeding behavior, energy homeostasis, and sexual activity (Bremelanotide and Melanotan 2). α-MSH is a nonselective agonist of melanocortin receptors MC1, MC3, MC4 and MC5. Melanotan 1 and Melanotan 2 activate the MC1 receptor, which is responsible for effects on skin pigmentation. Melanotan 2 and PT-141 both stimulate the MC3 and MC4 receptors which are responsible for the regulation of appetite, metabolism, and sexual behavior. However, PT-141 Bremelanotide does not stimulate the MC1 receptor.

A few synthetic analogues of α-MSH have been investigated for their apparent photoprotective effects against ultraviolet (UV) radiation from the sun, namely Melanotan (afamelanotide) and Melanotan II, referred to as Melanotan 2. Bremelanotide, another analogue of α-MSH similar to Melanotan 2, is currently under development for the treatment of sexual dysfunction. All of these melanotan peptides have significantly greater potencies than α-MSH, but with distinctive selectivity peptide profiles.

COMMON
Active substanceMelanotan II
POTENCY
Quantity10
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation10 milligrams per vial
Melanotan II is a cyclic heptapeptide analog of the alpha-melanocyte stimulating hormone (a-MSH), with the following molecular structure: It has been described to have superpotentmelanotropic activity in vitro. Its effect on tanning, like the effect of its similar peptide
25.00€
MGF

Mechano growth factor (MGF) is a novel splice variant of the Insulin-Like Growth Factor-1 (IGF-1), also known as IGF-1 Ec in humans and IGF-1Eb in rodents. It is actually originally called MGF because the RNA form of it is expressed in muscle tissues in response to the overload or/and damage of muscle growth tissue. The C-terminal peptide of the mechano growth factor (MGF) is a crucial region for the alternative splicing of the peptide. The alternative splicing in the MGF is brought about by the shift in the reading frame in which a specific C-terminal sequence (E-domain) is encoded by exon 5 and the first part of the exon 6. Another interesting point in MGF is that, because of the E domain it contains, MGF can act on muscles independently from the rest of the molecule. Furthermore, MGF can elicit very different effects with mGF promoting satellite cells proliferation and IGF-1 inducing differentiation (Dluzniewska et al. 2005).

Age Related Muscle Loss and MGF

MGF was suggested to play a number of physiological roles because the failure in its expression may result to age-related loss of skeletal function. Included in its functions is its ability to become a potent neuroprotective as supported by the study that has shown functional copies of the MGF cDNA to be expressed in a plasmid vector which then protected facial neurons after nerve damage (Dluzniewska et al. 2005). One such failure is called sarcopenia. It would also appear that with regards to age, the young have a better ability to respond to MGF (4), and that the elderly experience a decreased response to MGF which results in a decreased ability to stimulate the growth of new muscle tissue.

 

How does Mechano Growth Factor work? - Muscle Growth!

When mechanical overload is introduced to a muscle (as by weight training), the IGF-1 gene is released and is differentially spliced during the bodies response. Initially, it it is spliced to produce predominantly IGF-1Ec (called the MGF splice variant of IGF-1). This early splicing stimulates satellite cells into activation. Which in turn allows the activation of extra undamaged nuclei to grow new muscle fiber and tissue. The appearance of MGF also initiates the upregulation of new protein synthesis. After this initial splicing of IGF-1 into MGF, production then switches towards producing a systemic release of IGF-1Ea from the liver, which also upregulates protein synthesis as well. The expression of IGF-1 splice variants, over the course of the healing and regrowth phase of muscle repair is thought to be the primary mechanism by which the body produces new muscle tissue.

 

Recent Research and Studies Involving Mechano Growth Factor

Insulin like growth factor-1 (IGF-1) expression is implicated in myocardial pathophysiology, and two IGF-1 mRNA splice variants have been detected in rodents, IGF-1Ea and mechano-growth factor (MGF). Recent research has shown that the expression pattern of IGF-1 gene transcripts in rat myocardium from 1 h up to 8 wks after myocardial infarction induced by left anterior descending coronary artery ligation. In addition, we characterized IGF-1 and MGF E peptide action and their respective signaling in H9C2 myocardial-like cells in vitro. IGF-1Ea and MGF expression were significantly increased, both at transcriptional and translational levels, during the late postinfarction period (4 and 8 wks) in infarcted rat myocardium. Measurements of serum IGF-1 levels in infarcted rats were initially decreased (24 h up to 1 wk) but remained unaltered throughout the late experimental phase (4 to 8 wks) compared with sham-operated rats. Furthermore, specific anti–IGF-1R neutralizing antibody failed to block the synthetic MGF E peptide action, whereas it completely blocked IGF-1 action on the proliferation of H9C2 cells. Moreover, this synthetic MGF E peptide did not activate Akt phosphorylation, whereas it activated ERK1/2 in H9C2 rat myocardial cells. These data support the role of IGF-1 expression in the myocardial repair process and suggest that synthetic MGF E peptide actions may be mediated via an IGF-1R independent pathway in rat myocardial cells, as suggested by in vitro experiments. 

Recent studies have also discovered two clones of the hybridonoma secreting monoclonal antibodies to the mechano-growth factor have been developed by cell fusion technique. The monoclonal antibody of one clone recognizes the human MGF peptide that is absent in insulin-like growth factor-1 (IGF-1) which comprised mostly of amino acids from 87-111. Enzyme-linked immunosorbent assay (ELISA) has further shown that there is a high affinity binding constants with the full length of the MGF and the 87-111 fragments of the clones. These can then be used for the quantitation of the MGF through sandwich type assay.

POTENCY
Quantity2
UnitMilligram
PACKAGING
Quantity1
UnitVial
Mechano growth factor (MGF) is a novel splice variant of the Insulin-Like Growth Factor-1 (IGF-1), also known as IGF-1 Ec in humans and IGF-1Eb in rodents. It is actually originally called MGF because the RNA form of it is expressed in muscle tissues in response to the overload or/and damage of muscle growth tissue
15.00€
PAL-GHK (PAL-GHK)
Palmitoyl Oligopeptide (Pal-GHK) is a peptide speculated to mention the degradation of the matrix of the skin. Once fibroblasts, the cells that generate the skin matrix pick out higher ranges of GHK, they formulate other skin matrix assuming that they are really being engaged swift. Pal-GHK is a plenty refined version of GHK seeing that it penetrates the skin much better so it might well rouse the replenishment of the skin matrix completed topical wish. Wrinkle, aging as well as petty libretto are visibly dropped And also the skin causal agencies more impregnable Furthermore smoother.
 
Pal-GHK a version of GHK designed for better skin penetration,intended to stimulate skin matrix replenishment via topical application,leading,presumably,to wrinkle reduction,skin firming and other benefits.


POTENCY
Quantity10
UnitMilligram
PACKAGING
Quantity1
UnitVial
Presentation10 milligrams per vial
Palmitoyl Oligopeptide (Pal-GHK) is a peptide speculated to mention the degradation of the matrix of the skin. Once fibroblasts, the cells that generate the skin matrix pick out higher ranges of GHK
28.00€
Per Page      1 - 20 of 29